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suring natriuretic peptide levels in other solid organ 
transplantation may identify the cause and effect relation- 
ship between cyclosporine therapy and hypertension-re- 
lated diastolic dysfunction. 
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Reply to the Editoi:" 
In the stage of ventricular overload and especially 
failure, the secretion of natriuretic peptides (atrial natri- 
uretic peptide, ANP, and brain natriuretic peptide, BNP) 
is increased with compensatory, beneficial effects like 
enhanced iuresis, natriuresis, and inhibition of the renin- 
angiotensin system and the sympathetic nervous ystem. ~
ANP is predominantly released from atrial tissue stimu- 
lated by elevated wall stress. Theoretically, the bicaval 
technique in cardiac transplantation with significantly 
lower atrial dimensions and pressures 2 and thus wall stress 
should result in a decrease of the high level of ANP after 
standard cardiac transplantation. However, we could not 
measure a significant difference in the ANP levels be- 
tween the two transplantation techniques, an experience 
that was confirmed by EL Gamel and associates. Thus 
other mechanisms probably cause these high ANP levels. 
Whether one of these mechanisms i  related to primary or 
secondary effects of cyclosporine medication, as stated by 
EL Gamel's group, remains to be established. We could 
not find a correlation between the ANP and the cyclospo- 
rine trough level (r = -0.1164,p = 0.3828, n = 9). Other 
possible explantations for increased ANP levels are the 
denervation of the transplanted heart and a hypersensi- 
tivity of ANP-synthesizing cells to circulating cat- 
echolamines. 3 
EL Gamel and coworkers hould be congratulated for 
extending the knowledge of heart transplantation biology 
inasmuch as they found that the BNP level was signifi- 
cantly higher in the standard transplantation group, re- 
flecting a physiologic response to increased ventricular 
afterload. This represents a further argument in favor of 
the bicaval technique in cardiac transplantation. These 
new findings raise new questions: Are the drastically 
increased ANP levels after cardiac transplantation still 
beneficial? Are reinnervation procedures effective to op- 
timize regulation of ANP response? Does BNP level in 
patients after transplantation provide any prognostic in- 
formation comparable with patients after myocardial in- 
farction? 4 Is intravenous BNP valuable to improve post- 
operative hemodynamics? Is there any relation between 
the change of peptide levels and evolving rejection? We 
look forward with great interest o further progress in 
research in this context. 
Hans H. Sievers, MD 
Klinik fitr Herzchirurgie 
Medizinische Universitiit Liibeck 
Liibeck, Ge~7"nany 
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